{
    "url_original": "https://www.wsj.com/articles/novavaxs-new-covid-19-vaccine-might-be-late-to-the-party-11654697078?mod=markets_major_pos1",
    "url": "novavaxs-new-covid-19-vaccine-might-be-late-to-the-party-11654697078",
    "title": "Novavax’s New Covid-19 Vaccine Might Be Late to the Party",
    "sub_head": "Company will struggle to capture a sizable share of the Covid-19 vaccine market in the U.S.",
    "category_1": "Markets",
    "category_2": "Heard on the Street",
    "time": "2022-06-08 16:44:00",
    "body": "It’s one thing to arrive fashionably late to a party, it’s another thing to waltz in when the last guests are stumbling out the door.<br />For  Novavax ,  which on Tuesday cleared a key step toward U.S. Food and Drug Administration approval of its Covid-19 vaccine, the question is whether there is much partying left for vaccine makers as the Omicron surge fades and vaccination rates decline."
}